Kothari Ruchi, Kumar Vinod, Jena Rajender, Tunga Rashbehari, Tunga Binita Shrivastava
Intas Biopharmaceuticals Ltd.
PDA J Pharm Sci Technol. 2011 Jul-Aug;65(4):348-62. doi: 10.5731/pdajpst.2011.00745.
During storage of recombinant human parathyroid hormone (rhPTH) (amino acid residues 1-34) at 25 ± 2 °C, several impurities were obtained, which were detected by the tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and reversed-phase high-performance liquid chromatography (RP-HPLC) methods. To characterize the impurities generated, forceful chemical oxidation and deamidation was done. The oxidized positions were characterized by cyanogen bromide (CNBr) cleavage followed by liquid chromatography/mass spectrometry (LCMS) and further confirmed through N-terminal sequencing. Three oxidized variants were observed: sulfoxide of Met8 and Met18 and a variant comprising sulfoxide forms of both the methionine residues. LCMS results confirmed the presence of deamidated (+1 Da) and succinimide (-17 Da) variants. The low molecular weight impurities observed by tricine SDS-PAGE was confirmed to be peptide fragments by N-terminal sequencing and LCMS, resulting from cleavage at the C-terminal of asparagine (Asn)16, Asn33, and Asp30. Studies showed that rhPTH (1-34) undergoes oxidation, deamidation, and peptide bond cleavage during storage at pH 4.0 in acetate buffer.
Unlike currently licensed therapies to manage osteoporosis, parathyroid hormone (PTH) and its analogs represent a new class of anabolic agents, which act primarily to inhibit bone resorption and remodeling. The hormone's recombinant form is a bioactive peptide, 1-34 residues, which is inherently very unstable. Prior understanding of the molecular degradation pathway will help in development of a process that will yield a better product with respect to its quality and stability. The current work focuses on detailed characterization of the product-related impurities generated during storage of recombinant human PTH. The study depicted the various routes through which the molecule can degrade during its shelf life. Through a combination of forced degradation and accelerated study, it was established that the impurities were generated owing to oxidation, deamidation, and peptide bond cleavage of/at various amino acid residues. Until this study, it was presumed that oxidation is the primary route of degradation in PTH and most of the published reports were on native (1-84) forms of the hormone. The present research confirms that the recombinant hormone (1-34) degraded not only because of oxidation but that deamidation and peptide bond cleavage are also prominent modes of degradation. Therefore, owing to the unstable nature of the molecule it is suggested that stringent conditions should be maintained during manufacturing to obtain a stable molecule with fewer impurities.
重组人甲状旁腺激素(rhPTH)(氨基酸残基1 - 34)在25±2°C储存期间,产生了几种杂质,通过三羟甲基氨基甲烷 - 十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS - PAGE)和反相高效液相色谱(RP - HPLC)方法检测到这些杂质。为了表征产生的杂质,进行了强制化学氧化和脱酰胺反应。通过溴化氰(CNBr)裂解,随后进行液相色谱/质谱(LCMS)对氧化位点进行表征,并通过N端测序进一步确认。观察到三种氧化变体:Met8和Met18的亚砜以及包含两个甲硫氨酸残基亚砜形式的变体。LCMS结果证实了脱酰胺(+1 Da)和琥珀酰亚胺(-17 Da)变体的存在。通过N端测序和LCMS证实,三羟甲基氨基甲烷SDS - PAGE观察到的低分子量杂质是肽片段,是由天冬酰胺(Asn)16、Asn33和天冬氨酸(Asp)30的C端裂解产生的。研究表明,rhPTH(1 - 34)在醋酸盐缓冲液pH 4.0储存期间会发生氧化、脱酰胺和肽键裂解。
与目前用于治疗骨质疏松症的已获许可疗法不同,甲状旁腺激素(PTH)及其类似物代表了一类新型的促合成药物,其主要作用是抑制骨吸收和重塑。该激素的重组形式是一种具有生物活性的肽,含1 - 34个残基,本质上非常不稳定。对分子降解途径的先前了解将有助于开发一种在质量和稳定性方面能产生更好产品的工艺。当前工作聚焦于重组人PTH储存期间产生的与产品相关杂质的详细表征。该研究描绘了该分子在保质期内可能降解的各种途径。通过强制降解和加速研究相结合,确定杂质是由于各种氨基酸残基的氧化、脱酰胺和肽键裂解而产生的。在本研究之前,推测氧化是PTH降解的主要途径,并且大多数已发表的报告是关于该激素的天然(1 - 84)形式。本研究证实重组激素(1 - 34)不仅因氧化而降解,脱酰胺和肽键裂解也是突出的降解方式。因此,由于该分子的不稳定性质,建议在制造过程中保持严格条件以获得杂质较少的稳定分子。